Many at the town hall agreed solving the problem starts with eliminating the stigma tied to addiction

Town Hall Meeting In Southaven Talks About The Opioid Addiction Epidemic

http://www.localmemphis.com/news/local-news/town-hall-meeting-in-southaven-talks-about-the-opioid-addiction-epidemic/780813906

SOUTHAVEN, Miss (localmemphis.com) – Fighting the opioid addiction epidemic brought a team of Mississippi state agencies to Southaven Tuesday.

The Opioid Town Hall Rally is part of a series making its way through the Magnolia state

According to the Desoto County Coroner, there have been around 18 or 19 opioid or heroin related deaths so far in 2017. He said in all of 2016; there were 23.

“This is not about pointing fingers. This is about working together to find the solutions. We all have to take our fair share of responsibility but also the responsibility to bring solutions to the table, and that’s our effort,” said Steve Parker, Deputy Director of the Mississippi Board of Pharmacy.

All hands on deck approach Parker stressed was just one of the focuses at Tuesday’s town hall that drew about 100 people.

In the audience were people with organizations working to tackle the growing issue of opioid addiction, people who lost someone to addiction or struggled with it themselves, and local elected officials.

Organizers shared information on what opioids are and the destruction they can cause.

For instance, a representative with the Bureau of Narcotics shared Mississippi sees an unprecedented rise in the number of pharmacy burglaries and robberies.

They drove home that opioid addiction, whether it’s prescription pills or heroin, does not discriminate. It can hit people of all backgrounds.

Many at the town hall agreed solving the problem starts with eliminating the stigma tied to addiction.

“Until we take the stigma off a that and off a mental illness we’re going to continue to have people to die. People gotta be willing to stand up and say you know I’m not ashamed to talk about this anymore I got a loved one that has a disease,” said Marshall Fisher, Commissioner of the Mississippi Department of Public Safety.

 

“Our goal as a community is that we create no new addicts.”

Medical community, law enforcement partner against opioid epidemic

Groups working together to fight local opioid epidemic

http://www.southbendtribune.com/news/publicsafety/medical-community-law-enforcement-partner-against-opioid-epidemic/article_f5cd53bf-d40a-5096-b39f-ce9c731a4408.html

 

 

 

Medical community, law enforcement partner against opioid epidemic

SOUTH BEND — The murder of Dr. Todd Graham over an opioid prescription dispute last week

 

has galvanized the local medical community to seek help fighting a growing problem.

 

“The medical community has been working towards solutions to the opioid epidemic and in light of the recent events we realize we can no longer do this on our own,” said Dr. Nicole Riordan, an emergency physician at Memorial Hospital. “We must collaborate and work together to address this growing crisis that affects us all.”

Local law enforcement, medical professionals and other community organizations came together Wednesday to affirm an effort to work together to fight the area’s opioid crisis.

The partnership seeks to ensure healthcare providers are educated about appropriate prescribing practices and providers and patients are safe, Dr. Mark Fox, dean of the Indiana University School of Medicine-South Bend, said.

Many groups are already doing good work to combat the epidemic, but none of them have really been talking to each other, St. Joseph County Prosecutor Ken Cotter, said. What the groups are trying to do now, he said, is coordinate their efforts and become more active.

Following the shooting death of Graham, Cotter said, he was contacted by more than 20 doctors wanting to know not only what they could do to assure the safety of their patients and staff, but what they could do to fix the problem.

Part of law enforcement’s contribution in the collaboration is working with medical providers to establish “best practices” for dealing with threats and security.

“We don’t want them worrying about their safety and the safety of others,” Cotter said.

This will ensure medical providers are making the best decisions for their patients when prescribing medicine, he said, not making choices out of fear for their safety.

On the medical side, doctors will more actively work with law enforcement on the best ways to treat addictions to opioids. Although starting out there aren’t concrete plans to create things like committees, the goal is to start the partnership and the conversation.

While a partnership between doctors and law enforcement may be new, the area’s medical providers have already begun teaming up, Dr. Mark Thompson, an area general surgeon, said.

Representatives from both Memorial Hospital and Saint Joseph Regional Medical Center, along with South Bend Clinic and Allied Physicians, have started working together on community prescribing standards.

Last year in Indiana there were 109 opiod prescriptions written for every 100 patients, Thompson said.

“That’s staggering,” he said. “That’s too much.

“Our goal as a community,” Thompson said, “is that we create no new addicts.”

 

 

 

 

 

 

 

 

Your quality of life/health is just a bottom line issue for PBM/CVS

CVS Health removes 17 drugs as part of its 2018 formulary management strategy

http://www.drugstorenews.com/article/cvs-health-removes-1-drugs-part-its-01-formulary-management-strategy

WOONSOCKET, R.I. — CVS Health on Wednesday outlined its plan for formulary management in 2018, which includes the removal of 17 products from its Standard Control Formulary. The move is part of the company’s rigorous approach to formulary management that it began in 2012. Since starting this effort, the company said it will bring $13.4 billion in cumulative savings to its pharmacy benefits manager clients through 2018.

“We remove drugs only when clinically-appropriate, lower-cost (often generic) alternatives are available,” the company said. “Our targeted approach ensures minimum member disruption. For 2018, we estimate 99.76 percent of members will be able to stay on their current therapy. A proactive member and prescriber communication strategy helps members transition to clinically-appropriate medications, minimizing disruption.”

CVS Health said that its Standard Control Formulary, which covers more than 31 million lives, saw a post-rebate per-member-per-month cost of $85.90, compared with $121.12 among patients who are in its Standard Opt-Out Formulary, which doesn’t include formulary removals.

The drugs that the company is removing from the Standard Control Formulary are Doryx/Doryx MPC, Monodox, Follistim, Elelyso, Tanzeum, Sumavel Dosepro, Benicar/Benicar HCT, Effexor XR, Nuvigil, Seroquel XR, Zetia, Zubsolv, Jardiance, Synjardy/Synjardy XR, Dulera Hyalgan and Synvisc/Synvisc One.

In addition to removing these drugs from the formulary, CVS Health said it also was focused on an outcomes-based approach to management that aligns reimbursement with the value and outcome it delivers. As part of this effort, it is launching a cost cap-based program in three disease states.

The Transform Oncology Value program will focus on breast and non-small cell lung cancers, among others, and hold manufacturers responsible for adding value if a plan’s average cost is above a certain threshold for breast cancer patients.  It also calls for the manufacturer to contribute additional pre-determined value if a non-small cell lung cancer patient progresses to secondary therapy and key lab data has been obtained.

The Transform Obesity Value program, only open to members of the Standard Control Formulary or Advanced Control Formulary, would require additional value from manufacturers if members don’t achieve a minimum level of weight reduction within an initial assessment period. And Transform Respiratory Value program would require enhanced value from manufacturers if a greater number of members being treated for COPD escalate to triple therapy on a certain treatment than others.

The company also said it would be keeping an eye on treatments for autoimmune diseases, which is seeing a boom and this needs constant re-evaluation based on utilization and price.

“Consistent with our policy, as a new specialty product launches all existing products in the class will be re-evaluated to determine appropriate formulary placement and potentially removed or added to formulary,” CVS Health said that new entrants are expected in the hepatitis C class.

The company said its changes for autoimmune disorders and hepatitis C would be shared in mid— September.

Sessions: US prosecutors will help addiction-ravaged cities

prosecutors will help addiction-ravaged cities

http://abcnews.go.com/Health/wireStory/ag-sessions-address-opioid-epidemic-hard-hit-ohio-48980919

Sessions:

The Justice Department will dispatch 12 federal prosecutors to cities ravaged by addiction who will focus exclusively on investigating health care fraud and opioid scams that are fueling the nation’s drug abuse epidemic, Attorney General Jeff Sessions said Wednesday.

He unveiled the pilot program during a speech in hard-hit Ohio, where eight people a day die of accidental overdoses.

“In recent years some of the government officials in our country I think have mistakenly sent mixed messages about the harmfulness of drugs,” Sessions said. “So let me say: We cannot capitulate intellectually or morally unto this kind of rampant drug abuse. We must create a culture that’s hostile to drug abuse.”

Sessions said the group of prosecutors he has dubbed the “opioid fraud and abuse detection unit” will rely on data in their efforts to root out pill mills and track down doctors and other health care providers who illegally prescribe or distribute narcotics such as fentanyl and other powerful painkillers.

Such prescription opioids are behind the deadliest drug overdose epidemic in U.S. history. More than 52,000 Americans died of overdoses in 2015 — a record — and experts believe the numbers have continued to rise. Sessions has made aggressive prosecutions of drug crime a top priority, saying the deadly overdoses necessitate a return to tougher tactics.

The Health Department says opioid-related overdoses killed 3,050 Ohioans in 2015, with that number expected to jump sharply for 2016.

In June, the coroner serving the greater Columbus area said overdose deaths through April of this year rose to 173, a 66 percent jump from the same period a year ago.

The prosecutors will be based in U.S. attorney’s offices in the Middle District of Florida; the Eastern District of Michigan; the Northern District of Alabama; the Eastern District of Tennessee; Nevada; the Eastern District of Kentucky; Maryland; the Western District of Pennsylvania; the Southern District of Ohio; the Eastern District of California; the Middle District of North Carolina; and the Southern District of West Virginia.

In May, Sessions instructed the nation’s federal prosecutors to bring the toughest charges possible against most crime suspects. Critics assailed the move as a return to failed drug-war policies that unduly affected minorities and filled prisons with nonviolent offenders.

The announcement was a reversal of Obama-era policies that is sure to send more people to prison and for much longer terms.

Advocates warned the shift would crowd federal prisons and strain Justice Department resources. Some involved in criminal justice during the drug war feared the human impact would look similar.

Sessions said. “So let me say: We cannot capitulate intellectually or morally unto this kind of rampant drug abuse

I question what Session knows about INTELLIGENCE AND MORALITY…  The DEA has cut the Pharma’s production quota on opiates… legal opiate prescriptions are down and opiate OD deaths are UP..  and they keep quoting higher and higher drug OD deaths…  INTELLIGENCE would suggest that the legal opiate prescriptions are NOT THE CAUSE..

Besides it would appear that SESSION does not believe in personal responsibility… apparently our judicial system has put themselves in charge of the country’s morality.

Have you noticed that recently they have added the charges of Medicare/Medicaid/Insurance fraud and money laundering and when they make announcement about “busting” a prescriber/providers they lists all the ASSETS that they were able to seize.  Seizing illegal substances costs the DEA money… they have to inventory, store and destroy… it is a NET-NET-NET LOSS for the DEA to go after the CARTELS.   Where is the INTELLIGENCE within the DOJ/DEA as to the real underlying causes of all of these OD’s ?

This move by SESSION and recent moves by Chris CHRISTIE is just to funnel more MONEY into the war on drugs … as if the 81 billion/yr that we are already spending and > ONE TRILLION we have spent since the Control Substance Act 1970 was signed into law is not enough..  and Congress was already discussing adding 4.5 billion/yr. 

Notice that both Session & Christie are ATTORNEYS and they are proposing more MONEY being funneled into the JUDICIAL SYSTEM… the FRATERNITY that they are part of !  Could this be consider a form of SELF SERVING ?

 

At Your Defense: Are Physicians Actually Making More Mistakes?

At Your Defense: Are Physicians Actually Making More Mistakes?

http://journals.lww.com/em-news/Fulltext/2017/08000/At_Your_Defense__Are_Physicians_Actually_Making.11.aspx

Fatal medical errors are on the rise, alarmingly so when comparing the latest data with the watershed estimate from the Institute of Medicine that has been used for nearly two decades.

But a 2016 study by Martin Makary, MD, MPH, put the mean rate of deaths from medical error at more than double the IOM’s figure. Dr. Makary estimated that more than 250,000 deaths are now caused by medical error annually. (BMJ 2016;353:i2139.) This number is significantly higher than the IOM’s estimate of 44,000 to 98,000 in its report, “To Err is Human: Building a Safer Health System.” (Washington: National Academies Press; 2000.) But does this mean that physicians have actually made more fatal errors?

This “rise” in medical error may have less to do with an increase in incidence and more to do with growing recognition. Dr. Makary’s analysis estimated medical error to be the third most common cause of death, after only heart disease (614,348) and cancer (591,699) based on the CDC’s number of deaths in 2013. (http://bit.ly/2sHsAd1.) The CDC does not traditionally recognize medical error as a cause of death, but it would likely be underreported if it did. Nevertheless, recognizing that medical error is a substantial cause of mortality brings to light another question: Has medicine done anything to help physicians reduce it?

Back to Top | Article Outline

The Anatomy of Error

Claims of medical negligence are traditionally based on clinician error, which can be broken down into three categories. Claims can be based on allegations of diagnostic error, in which the wrong diagnosis was made or a delay in diagnosis led to patient injury. Treatment errors include medication errors like selecting the wrong intervention or treatment, delay in treatment, or the failure to perform an operation or a procedure successfully. Then there are preventive errors, which result from failure to provide prophylactic treatment, sufficient monitoring, or timely follow-up care.

A malpractice claim is founded on the allegation that a clinician failed to meet the standard of care due to his error in diagnosis, treatment, or opportunity to prevent patient injury. In fact, the story painted by a plaintiff attorney tends to portray an isolated image of a physician generating too narrow of a differential diagnosis or failing to address an abnormal lab value or stabilize an abnormal vital sign promptly. A defense attorney would never point out the three traumas, two septic patients, and one in-house code that the defendant physician also treated because this would garner no sympathy for the defendant.

The other type of error outlined in the 1999 IOM report, system error, was identified as the bigger problem in health care. System error contributes to wrong medication dosing when medicines are available in very high concentrations, wrong diagnostic testing when electronic health record screens display test selections too closely together, and delay in treating emergency medical conditions when specialists are not available.

EHRs are a common source of system error, such as when they prevent physicians from efficiently sharing relevant clinical information, creating unreadable documents and drowning us in a sea of useless data. (Table.)

Back to Top | Article Outline

Causes of Diagnostic Errors

Identifying diagnostic error is only part of the picture when trying to understand malpractice claims. Identifying the primary and contributing factors to diagnostic error brings us closer to understanding how we can prevent them. A 2007 study by Kachalia, et al., revealed that 79 (65%) of the 122 closed malpractice claims were due to missed or delayed ED diagnosis. (Ann Emerg Med 2007;49[2]:196.) The causes of these diagnostic errors were multifactorial, but the most common contributing factors included failure to order appropriate diagnostic tests, inadequate medical history or physical examination, and incorrect interpretation of diagnostic and laboratory tests, such as x-ray (62%), CT (7%), or ECG (10%).

The Kachalia study analyzed the causes of diagnostic errors, and attributed cognitive processes as the most significant contributory factor (96%). A more recent study by the Doctor’s Company cited inadequate patient assessment (52%) as the most common cause of diagnostic error. (http://bit.ly/2sHATFV.) Both studies, however, seem to underestimate the impact of ineffective workflows, cumbersome EHRs, and crowded EDs on cognitive processes. Any practicing EP would agree that our cognitive processes deteriorate at the 11th hour of a shift, after the 25th patient seen, and when we are overwhelmed by frenetic disruptions.

A Two-Pronged Approach

It is clear that we have failed to reach the IOM’s stated goal of achieving a 50 percent reduction in medical error by 2004. If the current estimates are true, we have experienced a fivefold increase in medical error. Clinical decision support has not been the panacea that was hoped for.

What we should hope for in the near future are EHRs with intuitive, user-centered design that bring only the most important clinical information to the clinician, interoperability that allows for seamless information exchange between outpatient and inpatient clinicians, and intelligent clinician decision support that avoids the mindless, irrelevant window pop-ups and alerts us only when we really need alerting.

We physicians can reduce errors in our daily practice by collaborating with our hospital administrators to create the most efficient clinical workflows, establishing evidence-based protocols that still allow for sound clinical judgment and implementing a robust risk management program in emergency medicine.

Share this article on Twitter and Facebook.

Access the links in EMN by reading this on our website or in our free iPad app, both available at www.EM-News.com.

Comments? Write to us at emn@lww.com.

Police: Pharmacist refuses to fill prescription unless woman removes clothes

Police: Pharmacist refuses to fill prescription unless woman removes clothes

http://wivb.com/2017/08/01/police-pharmacist-refuses-to-fill-prescription-unless-woman-removes-clothes/

NIAGARA FALLS, N.Y. (WIVB) — Niagara Falls police say a pharmacist coerced a woman into removing her clothes before filling her prescription Tuesday morning.

Robert Kenzia, 81, is a licensed pharmacist at McLeod’s Pharmacy in Niagara Falls.

Police charged him with Coercion after they say he refused to fill a woman’s prescription unless she removed clothing in front of him.

In addition to that, police say Kenzia threatened the woman, saying he would tell other pharmacies not to fill her prescription if his demands were not met.

The Drug Enforcement Administration (DEA) is investigating to see if any illegal activity occurred at the pharmacy.

Police say they suspect there may be other victims. If anyone has information that would benefit their investigation, police can be reached at (716) 286-4591.

Chronic Widespread Pain Patients More Likely to Die Early

Chronic Widespread Pain Patients More Likely to Die Early

Lifestyle may explain excess mortality in fibromyalgia and other chronic pain patients

https://www.medpagetoday.com/Rheumatology/Fibromyalgia/66955?xid=nl_mpt_Weekly_Education_2017-08-02&eun=g5705800d1r

People who have chronic widespread pain die earlier than those without chronic pain, reported new research from the United Kingdom, and lifestyle may play a significant role in their mortality.

Chronic widespread pain patients who participated in UK Biobank — a cohort of 500,000 people ages 40 to 69 recruited throughout Great Britain — had a mortality risk ratio (MRR) of 2.43 (95% CI 2.17-2.72), according to Gary J. Macfarlane, MD, PhD, of the University of Aberdeen, and colleagues. This excess risk was substantially reduced after adjusting for low levels of physical activity, high body mass index (BMI), poor quality diet, and smoking.

“The evidence is now clear that persons with chronic widespread pain experience excess mortality,” the researchers wrote in Annals of the Rheumatic Diseases. “UK Biobank results considerably reduce uncertainty around the magnitude of excess risk, and demonstrate that the risk is unlikely to be due to the experience of pain per se, but is substantially explained by lifestyle factors associated with having pain (poor diet, low levels of physical activity, smoking, higher BMI).”

It’s the largest study to examine the relationship between chronic widespread pain and mortality, the authors indicated, and has considerably more detailed information about potential mediators of any excess risk associated with widespread pain and death.

UK Biobank included 7,130 participants who reported “pain all over the body” for more than 3 months, and 281,718 people who did not have chronic pain. These two sub-cohorts represented the study population for the current analysis. Both groups had the same median age (58 years), but the chronic pain group was less likely to be male (36.3% versus 50%) and more likely to be heavier than normal weight (80.4% versus 63.5%). They also were twice as likely to be a current smoker (18.6% versus 9.3%) and were less physically active. Participants in UK Biobank were recruited throughout Great Britain from 2006 to 2010; information about deaths in this group was available through mid-2015.

The researchers found that, after adjusting for age and sex and excluding deaths that occurred in the first two years, participants with chronic widespread pain had a more than twofold risk of dying in the follow-up period. Adjusting for age and sex, they found that excess risk of death stemmed from cancer (MRR 1.73; 95% CI 1.46-2.05), cardiovascular disease (MRR 3.24; 95% CI 2.55-4.11), respiratory disease (MRR 5.66; 95% CI 4.00-8.03), and other disease-related causes (MRR 4.04; 95% CI 3.05-5.34).

They also examined to what extent factors associated with pain also predicted death. They found that age- and gender-adjusted risk of death was higher for participants in the two highest BMI categories than for people of normal weight: those who were 35-39 kg/m2 had an MRR of 5.54 (95% CI 5.08-6.03), and those 40kg/m2 or greater had an MRR of 9.02 (95% CI 8.23-9.89). They also observed that participants who reported no walking, versus those walking 1-100 minutes per week, had an MRR of 4.15 (95% CI 3.77-4.57). People who reported no moderate physical activity, versus those who reported 1-60 minutes of moderate physical activity per week, had an MRR of 2.95 (95% CI 2.74-3.19). Risk of death also was higher in current smokers, who had an MRR of 2.54 (95% CI 2.39-2.70) versus non-smokers.

When they adjusted the risk models to see how lifestyle variables like BMI, physical activity, smoking, and diet might attenuate the relationship between chronic widespread pain and excess mortality, they still saw an excess risk of cardiovascular and respiratory deaths, but no longer an excess risk of cancer death.

Lifestyle factors are important intervention targets for patients with chronic widespread pain, the authors concluded. They observed that optimal management of fibromyalgia should include exercise, for example, but that is not often provided in a structured way to help patients make long-term behavioral changes.

“Few patients with chronic widespread pain or fibromyalgia receive specific supported care in improving diet or stopping smoking,” they wrote. “The data from this study show that changing the habits of persons with chronic widespread pain to be similar to persons without chronic widespread pain could reduce mortality by around 35%.”

The researchers also incorporated their results into a meta-analysis with five other published reports to evaluate evidence linking pain and mortality. Studies included in the meta-analysis were observational, used a population sampling frame, identified widespread pain or chronic widespread pain (including fibromyalgia), and quantified the relationship between chronic widespread pain and death.

“The meta-analysis of this relationship shows that all 6 studies find excess mortality and estimate the excess risk across all studies at 59%, although there is significant heterogeneity,” the authors wrote. “Similar excesses of cancer and cardiovascular mortality are observed.”

“In UK Biobank, adjustment for lifestyle factors substantially reduced the excess risk, and this observation is consistent with them mediating the relationship between chronic widespread pain and mortality,” they added.

Wisdom from Ken McKim

Purdue Pharma has to help pay for treatment of abuse of ILLEGAL SUBSTANCES ?

Pharma company settles lawsuit in Canada preventing further action on opioid crisis

www.rumblenews.net/pharma-companies-lawsuits-opioid-crisis/

Pharmaceutical company Purdue, which produces the prescription drug OxyContin that is causing widespread overdoses in Canada and the US, are on the verge of a settlement with provincial governments which could bar any further action from being taken against them in combating the opioid crisis.

As the Globe and Mail reported on Monday:

Purdue Pharma, maker of the prescription painkiller OxyContin, has agreed to pay $20-million, including $2-million to provincial health insurers, to settle the long-standing class-action suit. An Ontario court judge approved the proposed national settlement two weeks ago.

On Tuesday the settlement was approved by Nova Scotia, one of the last provinces that had yet to accept the terms of the agreement.

The lawsuit was the result of a class action on the part of up to 1,500 Canadians who suffered from addiction. But some are opposed to the decision as an acceptance of the funds would prevent any further legal action from being brought against the company as a condition of the settlement.

The settlement says class members and provincial health insurers are barred from “initiating, asserting or prosecuting any claim, action, litigation, investigation or other proceeding in any court of law…or any other forum.”

According to the most recent numbers from the Canadian Institute for Health Information, the settlement accounts for only a fraction of the money that is spent to combat addiction. as the Globe pointed out:

The provinces’ public drug plans spent $423.3-million over a five-year period on medications used for addiction to prescription painkillers and illicit opioids.

The National Post reported on Tuesday, a few provinces have yet to accept the settlement which does not find the drug company liable for the addictions its drugs caused.

Purdue did not admit liability in the national settlement, which still must be approved by courts in Saskatchewan and Quebec before individual payments that the judge estimated to average between $13,000 and $18,000 begin to flow.

Similar lawsuits have taken place in the United States which is dealing with a similar opioid problem fueled by the same pharmaceutical drugs.

In early July the Washington Post reported that the Justice Department had reached its first settlement in a slew of lawsuits that have been brought against several companies including Purdue.

Mallinckrodt Pharmaceuticals reached a $35 million settlement Tuesday to resolve allegations that the company failed to report signs that large quantities of its highly addictive oxycodone pills were diverted to the black market in Florida, where they helped stoke the opioid epidemic.

In 2007, Purdue and its top executives were found guilty of criminal violations in the companies branding which mislead doctors and patients on OxyContin’s addictive qualities. Then president of the company Michael Friedman, and others, pleaded guilty to the charges and were fined $34.5 million. According to a New York Times report on the suit:

To resolve criminal and civil charges related to the drug’s “misbranding,” the parent of Purdue Pharma, the company that markets OxyContin, agreed to pay some $600 million in fines and other payments, one of the largest amounts ever paid by a drug company in such a case.

The most recent numbers from a Canadian government report, which only recently began to collect data on opioid deaths, found that in 2016:

there were 2,458 apparent opioid-related deaths in Canada, although this figure may change as more updated data become available.

Even with the epidemic, sales of prescription opioids have continued to increase in Canada according to data from QuintilesIMS reported on by the Globe and Mail in March of 2017:

Retail pharmacies across Canada dispensed 19 million prescriptions for opioids in 2016, up slightly from 18.9 million in 2015…Prescriptions climbed six per cent over the past five years.

Blue Cross determines ADDICTION by the number of LEGAL RXS beneficiaries filled ?

Opioid addiction quintupled since 2010 and 10 other findings in new study

http://www.mlive.com/news/index.ssf/2017/07/opioid_addiction_rate_has_quin.html